The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Keeps Halo Pharma to drive independent growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The goal is to better support drug developers as programs move from laboratory research into clinical trials
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
Subscribe To Our Newsletter & Stay Updated
